Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04653246 · ClinicalTrials.gov registry record · Phase 2
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
A Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant, sponsored by Jacob Laubach, MD.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04653246: Active Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant, sponsored by Jacob Laubach, MD.
NCT04653246 is a Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant that is active but no longer recruiting, run by Jacob Laubach, MD. The registered enrollment target is 52 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04653246, a Phase 2 study of Multiple Myeloma and Autologous Stem Cell Transplant, is active but no longer recruiting, sponsored by Jacob Laubach, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
Primary Outcome
proportion of patients who have achieved VGPR or better, according to International Myeloma Working Group (IMWG) criteria (Kumar 2016), by the end of two cycles of induction treatment
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Isatuximab
- DRUG Bortezomib Injection
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2029-01-13 |
| Phase | Phase 2 |
What the registry record for NCT04653246 still lists
NCT04653246 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (90% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Dexamethasone is the first listed.
NCT04653246 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04653246 about?
NCT04653246 is a clinical study titled "Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM". This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.
What is the current status of trial NCT04653246?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-07-13. Estimated completion is 2029-01-13.
What conditions does trial NCT04653246 study?
This clinical trial studies the following conditions: Multiple Myeloma, Autologous Stem Cell Transplant, Newly Diagnosed Multiple Myeloma (NDMM).
What interventions are being tested in trial NCT04653246?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Isatuximab (DRUG), Bortezomib Injection (DRUG).
Who is sponsoring clinical trial NCT04653246?
This trial is sponsored by Jacob Laubach, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04653246 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04653246's enrollment target sits among peer trials
52 245th of 438 higher than 189 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI